Literature DB >> 25522897

Is it a time to modify the BCLC guidelines in terms of the role of surgery?

Norihiro Kokudo1.   

Abstract

Mesh：

Year:  2015        PMID： 25522897     DOI： 10.1007/s00268-014-2915-2

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  10 in total

1.  Portal hypertension: contraindication to liver surgery?

Authors:  Lorenzo Capussotti; Alessandro Ferrero; Luca Viganò; Andrea Muratore; Roberto Polastri; Hedayat Bouzari
Journal:  World J Surg       Date:  2006-06       Impact factor: 3.352

2.  Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

Authors:  J M Llovet; J Fuster; J Bruix
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

3.  Impact of severe oesophagogastric varices on liver resection for hepatocellular carcinoma in cirrhotic patients.

Authors:  Hsiao-Tien Liu; Shao-Bin Cheng; Cheng-Chung Wu; Hong-Zen Yeh; Chi-Sen Chang; John Wang
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication?

Authors:  Roberto Santambrogio; Michael D Kluger; Mara Costa; Andrea Belli; Matteo Barabino; Alexis Laurent; Enrico Opocher; Daniel Azoulay; Daniel Cherqui
Journal:  HPB (Oxford)       Date:  2012-10-24       Impact factor: 3.647

7.  Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis.

Authors:  Yuichiro Kawano; Atsushi Sasaki; Seiichiro Kai; Yuichi Endo; Kentaro Iwaki; Hiroki Uchida; Kohei Shibata; Masayuki Ohta; Seigo Kitano
Journal:  Ann Surg Oncol       Date:  2008-03-27       Impact factor: 5.344

8.  Is portal hypertension a contraindication to hepatic resection?

Authors:  Alessandro Cucchetti; Giorgio Ercolani; Marco Vivarelli; Matteo Cescon; Matteo Ravaioli; Giovanni Ramacciato; Gian Luca Grazi; Antonio Daniele Pinna
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

9.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

10.  Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Norihiro Kokudo; Keiji Sano; Hiroshi Imamura; Yoshifumi Beck; Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2009-01
  10 in total
  3 in total

1.  Comparison of the Outcomes of Patients with Hepatocellular Carcinoma and Portal Hypertension After Liver Resection Versus Radiofrequency Ablation.

Authors:  Noboru Harada; Ken Shirabe; Takashi Maeda; Hiroto Kayashima; Shintaro Takaki; Yoshihiko Maehara
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

Review 2.  Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective.

Authors:  Tian Yang; Wan-Yee Lau; Han Zhang; Bin Huang; Jun-Hua Lu; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

3.  Surgical Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices.

Authors:  Noboru Harada; Ken Shirabe; Takashi Maeda; Hiroto Kayashima; Teruyoshi Ishida; Yoshihiko Maehara
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.